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Introduction
Part 1 of this series discussed NSAIDs, paracetamol, and topical 
analgesics as the treatment classes of choice for predominantly 
mild-to-moderate acute pain. Part 2 considered the use of 
opioids and the atypical opioids, tramadol and tapentadol, for 
mainly moderate-to-severe nociceptive pain. Part 3 explores the 
mechanisms of action and place in therapy of the anticonvulsants 
and antidepressants in neuropathic and other chronic pain 
management, and will briefly discuss other notable analgesics 
for this indication.
Pain was previously functionally classified as either nociceptive 
or neuropathic. Nociceptive pain is defined as “pain that arises 
from actual or threatened damage to non-neural tissue and is 
due to the activation of nociceptors.”1 A normally functioning 
somatosensory nervous system is implied in this definition. 
Conversely, neuropathic pain is succinctly defined as “pain caused 
by a lesion or disease of the somatosensory nervous system.”1 
There are several causes of neuropathic pain, and it can arise 
from the central or peripheral nervous system. Common causes 
include painful diabetic neuropathy, postherpetic neuralgia, 
HIV neuropathy, and stroke. Patients exhibiting features of both 
nociceptive and neuropathic pain were regarded as having 
“mixed pain”.
The binary classification of pain was subsequently challenged, as 
it leaves patients unclassified who do not have both non-neural 
tissue damage or nervous system lesions.2 The designation 
“nociplastic pain” was introduced for these groups, and is 
defined as “pain that arises from altered nociception despite no 
clear evidence of actual or threatened tissue damage causing 
the activation of peripheral nociceptors, or evidence for disease 
or lesions of the somatosensory system causing the pain.”1 
Subsequently, patients with fibromyalgia, complex regional pain 
syndrome, or irritable bowel syndrome are better described as 
having predominantly nociplastic pain.
The lack of a clear aetiology in nociplastic pain conditions 
often make the management of the pain – and the frequently 
associated comorbidities – difficult and complex. Yet an 
identifiable aetiology, such as in nociceptive or neuropathic 
pain, does not guarantee adequate and easily attainable pain 
control. For example, it has been suggested that more than half 
of patients with neuropathic pain will not respond to single 
drug therapy.3 Clinical implementation of the findings of studies 
assessing drugs for neuropathic pain is therefore challenging, 
because most of the trials were conducted with single drugs. 
As many patients will likely require combination drug therapy, 
the paucity of head-to-head studies of combinations necessitate 
that comparisons of combinations be made on relative response 
rates of individual drugs. This approach is often inaccurate, 
and these studies are generally too short for a comprehensive 
assessment of efficacy in chronic pain (generally 6–8 weeks).4 
Nevertheless, the anticonvulsants and antidepressants are 
considered first-line therapy for neuropathic pain, as endorsed 
by several pain societies.5
Anticonvulsants
Mechanism of action
The management of neuropathic pain was initially approached 
according to perceived aetiology, but better understanding 
of the underlying pathophysiology led to a more mechanistic 
approach.6 The main objective in neuropathic pain management 
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is to decrease spontaneous firing of damaged nerves, and/
or to attenuate ascending hyperalgesic and allodynic signals. 
The anticonvulsants are theoretically well suited for this, as 
most exhibit some form of neuronal transmission inhibition 
via ion channel modulation or inhibitory neurotransmitter 
modulation.4,6,7 However, the exact mechanisms of action in 
neuropathic pain relief are not fully understood.
Pregabalin and gabapentin – known as the gabapentinoids – 
are both gamma-aminobutyric acid (GABA) analogues. Their 
structural similarity to GABA facilitates central nervous system 
penetration, but they do not have any GABAergic activity.8,9 
The principal mechanism of action is the selective inhibition of 
the predominantly presynaptic alpha 2-delta subunits of the 
voltage-gated calcium channels of neurons.10 Inhibition of this 
channel reduces the firing and neurotransmitter release of the 
neuron (Figure 1).
Place in therapy
Despite the theoretical rationale for using anticonvulsants in 
neuropathic pain, the evidence for their use is restricted. A 2013 
overview of systematic reviews7 – consisting of 10 reviews of 91 
studies, including 17 955 patients – assessing the anticonvulsants 
for neuropathic pain, found a wide discrepancy between the 
different drugs. The review found that only the gabapentinoids 
(pregabalin and gabapentin) had good quality evidence for 
their use in painful diabetic neuropathy, postherpetic neuralgia, 
and central neuropathic pain.7 Some low quality evidence was 
found for the use of carbamazepine in trigeminal neuralgia 
and painful diabetic neuropathy. Anticonvulsants such as 
phenytoin, lamotrigine, sodium valproate, and topiramate, 
as well as the benzodiazepine clonazepam, did not show any 
evidence of efficacy.7 Another systematic review also found that 
a newer anticonvulsant, levetiracetam, did not have evidence of 
efficacy in painful neuropathy.12 Nonetheless, these drugs may 
still be considered add-on or second-line therapy in patients 
unresponsive to first-line pharmacological treatments.4
Of note is that pregabalin was found not to be effective for HIV 
neuropathy in an extensive clinical trial.13 The authors postulated 
that this finding may be due to a high placebo response rate 
combined with a small treatment effect, or that pregabalin 
is only effective in a defined subpopulation. The Infectious 
Diseases Society of America currently recommends gabapentin 
as first-line therapy for these patients as part of their clinical 
practice guidelines,14 but the recommendation is based on a 
small study involving only 26 patients.15 By contrast, the South 
African Standard Treatment Guidelines currently recommend 
carbamazepine or the tricyclic antidepressant, amitriptyline, for 
HIV-associated neuropathic pain.16
The use of carbamazepine may be limited by its adverse effect 
profile. Common, mild adverse reactions include sedation, 
nausea, and vomiting, whereas severe reactions involving the 
skin (Stevens-Johnson syndrome/toxic epidermal necrolysis 
and other hypersensitivity reactions) and bone marrow 
(agranulocytosis) are rare.17 Hypersensitivity reactions involving 
the skin have been linked to human leukocyte antigen complex 
(HLA)-B*1502 in the Chinese population,18 and with HLA-A*3101 
in the European population.19
The gabapentinoids generally exhibit dose-dependent adverse 
effects, most notably dizziness and sedation.20 Pregabalin showed 
better responses for painful neuropathic conditions at higher 
dosages,21 and it is therefore recommended that pregabalin 
be started at a low dose, and titrated up to effect.4,22 Recent 
evidence suggests that the gabapentinoids should be prescribed 
with caution in those receiving opioids. Two studies have found 
that in patients receiving prescription opioids, concomitant use 
of gabapentinoids was associated with a significant dose-related 
increase in the risk of opioid-related mortality.23,24
Figure 1: A hyperexcitable neuron associated with neuropathic pain (left pane). Binding of the gabapentinoids to the alpha 2-delta subunit of the 
calcium channel reduces the neuron’s excitability by attenuating neurotransmitter release (Adapted from Shim11).
α2-δ subunit - Alpha 2-delta subunit
Ca2+ channel - Calcium channel
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Antidepressants
Mechanism of action
The main mechanism by which the antidepressants exert their 
analgesic effect is thought to be by augmenting descending 
inhibitory pathways in the spinal cord.20,25,26 Augmentation is 
achieved by increasing the concentration of synaptic amine 
neurotransmitters (mainly serotonin and noradrenaline) by 
inhibiting the transporters involved in their reuptake into 
the presynaptic terminal.20,25,26 It appears that increasing 
noradrenaline concentrations in the spinal cord leads to greater 
analgesic effects compared to serotonin, based on several 
animal and human studies.27,28 In animal models, noradrenaline 
reuptake inhibition appears to be vital to the attenuation of 
neuropathic pain.25 A more recently proposed mechanism of 
the antidepressants’ analgesic effects relate to stimulation of the 
peripheral adrenergic system.29 It has also been suggested that 
a reciprocal relationship exists between pain and depression: 
pain may lead to (and worsen) depression, and depression may 
worsen pain.30--32 The antidepressants therefore seem to improve 
pain in some situations by addressing the underlying depression, 
including pain perception.30 Nevertheless, the antidepressants 
appear to possess inherent analgesic activity, as evidenced by 
the observations that they are effective even in non-depressed 
patients, and that pain relief occurs much sooner than the 
expected antidepressive effect, and at much lower doses than 
needed for depression.20
Antidepressants with notable serotonergic and noradrenergic 
reuptake inhibition include the tricyclic antidepressants (TCAs), 
such as amitriptyline, and the serotonin-noradrenaline reuptake 
inhibitors (SNRIs), such as duloxetine and venlafaxine (Figure 2).
Place in therapy
Several pain societies recommend TCA and SNRI antidepressants 
– as well as the anticonvulsants described above – as first-line 
pharmacological therapy for neuropathic pain.5 While there is 
a theoretical rationale for considering other noradrenergically-
driven antidepressants, weak evidence or lack of clinical trials 
have limited the recommendation of such drugs, including 
bupropion, mianserin, mirtazapine, and reboxetine.26,34-36
Current international guidelines5 broadly recommend the TCAs 
and SNRIs for neuropathic pain, but emphasis is placed on the 
TCAs for postherpetic neuralgia and neuropathic pain of central 
origin. Second-line treatment options include the atypical 
opioids (tramadol and tapentadol), strong opioids, and topical 
analgesics.5
In deciding on patient-specific treatment, the choice of first-
line therapy generally depends on patient characteristics, the 
evidence for a specific drug, previous drug experience, and 
cost. The TCAs have the highest therapeutic efficacy and are 
generally inexpensive, but their use and dose escalation is 
limited by adverse effects, such as sedation and anticholinergic 
effects (commonly dry mouth, constipation, and palpitations).26 
The SNRIs tend to exhibit less of these adverse effects,20 but are 
not as efficacious in neuropathic pain relief as the TCAs,37 and 
are usually more costly. Of note is that the SNRI duloxetine is 
approved by the American Food and Drug Administration (FDA) 
for the additional indications of fibromyalgia and, more recently, 
chronic musculoskeletal pain, including osteoarthritis and 
chronic lower back pain.38 The trials included for the registration 
of duloxetine for chronic musculoskeletal pain were conducted 
by the manufacturer and, while a small but significant reduction 
in pain was seen with duloxetine compared to placebo, one trial 
found that this difference in response was not sustained beyond 
3 months.38
To date, the selective serotonin reuptake inhibitors (SSRIs) 
have shown inconclusive evidence of efficacy in various pain 
conditions, including neuropathic pain. It may, however, be 
beneficial for a subset of patients with chronic pain, notably 
those whose pain is a component of somatic expression of their 
depression.4 Treating the depressive symptoms with SSRIs may 
then improve or even resolve the associated pain.4,39,40
Other medications
Cannabinoids
Much controversy exists in the medical and lay literature 
regarding the synthetic and phytocannabinoids for medical use. 
The cannabinoids are thought to exert their analgesic effect 
primarily through the effect of tetrahydrocannabinol (THC) on 
the endocannabinoid system.41 The best evidence for medical 
efficacy lies with rare forms of childhood epilepsy, namely 
Lennox-Gastaut42 and Dravet43 syndromes, and the medical 
phytocannabinoid, cannabidiol, is FDA approved for these 
indications.44
Figure 2: Mechanism of action of the SNRIs, TCAs, and SSRIs (Adapted 
from Stevens33)
SNRI - Serotonin and noradrenaline reuptake inhibitor
TCA - Tricyclic antidepressant
SSRI - Selective serotonin reuptake inhibitor
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The evidence for the use of cannabinoids for chronic pain is 
unclear. A 2015 systematic review and meta-analysis found 
a statistically non-significant reduction in chronic pain, but 
heterogeneity of indications and type of cannabinoid limited 
its interpretation.45 A recent systematic review46 assessed the 
use of synthetic and phytocannabinoids for chronic neuropathic 
pain. Sixteen studies with 1750 participants were included, and 
evaluated inhaled herbal, oromucosal sprayed, and synthetic 
cannabinoids. While the quality of evidence was low and sample 
sizes small, the review found that the potential benefits of 
cannabis-based medicine in chronic neuropathic pain might 
be outweighed by their potential harms. Illustrating this is the 
finding that the number of patients needed to treat (NNT) for 
50% pain relief was 20 (95% confidence interval [CI] 11–100), 
whereas the number of patients needed to harm (NNH) for 
the development of a nervous system adverse effect was 3 
(95% CI 3–6). The NNH for the development of a psychiatric 
disorder was 10 (95% CI 7–16).
Ketamine
The use of ketamine for chronic pain relief has gained interest in 
recent years. The analgesic mechanism of ketamine is thought to 
be mediated by non-competitive N-methyl-D-aspartate (NMDA) 
receptor antagonism.47 Evidence for its use lies with acute 
postoperative pain relief, with some evidence indicating efficacy 
in cancer pain.47 Ketamine for chronic non-cancer pain does not 
currently have a strong evidence base, and lack of long-term 
safety data and effective routes of administration other than 
intravenous or subcutaneous prohibits its recommendation.47-49 
Nevertheless, several pain societies have advocated the use of 
ketamine in both acute50 and chronic51 pain. The authors of these 
guidelines state that while they support ketamine as a viable 
analgesic option, the recommendations are consensus-based 
and have low levels of evidence, varying by condition and dose 
range.
Conclusion
Chronic pain is complex, and often difficult to manage. This may 
be due to our current incomplete understanding of chronic pain 
mechanisms and definitive targets, as well as the mechanisms of 
action of the currently available drugs. While this review focused 
on pharmacotherapy, the involvement of a multidisciplinary 
team and multimodal analgesia is of paramount importance. 
The evidence for the use of drugs for neuropathic pain presently 
lies with the gabapentinoids, TCAs, and SNRIs. Topical analgesics, 
atypical opioids, strong opioids, and SSRIs can be considered 
for add-on or second-line therapy. Further studies are needed 
to clearly assess the efficacy and safety of the cannabinoids and 
ketamine.
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